Intensifying Competition and Lower Selling Prices Resulting from Revisions to Medical Reimbursement Rates and Reimbursement Prices
First written in FY2016. 26 of 34 entries say "Restated". Latest entry: FY2026-H1.
The whole theme swung hardest in 2025: 3 of 8 companies on the "Worse" side.
6 other companies' latest entry also says "Restated".
- FY2026-H1RestatedAnnual report
「During the interim consolidated accounting period, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
States that there have been no new business or other risks or material changes to existing risks. - FY2025RestatedAnnual report
「In Japan, policies to improve the quality of healthcare and contain medical costs are being advanced, and medical fees, drug prices, and official reimbursement prices for specified insured medical materials are revised once every 2 years. Changes in healthcare policy could intensify competition among companies and lead to lower selling prices, potentially affecting the operating results and financial position of the Group.」
Continues to identify revisions to medical fees and other prices, policies to contain medical costs, and the potential for intensified competition and lower selling prices as major risks. - FY2025-H1RestatedAnnual report
「During the interim consolidated accounting period, there were no new business or other risks, nor any material changes to the business or other risks described in the annual securities report for the previous fiscal year.」
States that there have been no new business or other risks and no material changes to existing risks. - FY2024RestatedAnnual report
「In Japan, policies to improve the quality of healthcare and contain medical costs are being advanced, and medical fees, drug prices, and official reimbursement prices for specified insured medical materials are revised once every 2 years. Changes in healthcare policy could intensify competition among companies and lead to lower selling prices, potentially affecting the operating results and financial position of the Group.」
Continues to identify revisions to medical fees and other prices, policies to contain medical costs, and the potential for intensified competition and lower selling prices as major risks. - FY2024-Q3RestatedAnnual report
「During the first nine months of the fiscal year, there were no new business risks and no material changes to the business risks described in the previous fiscal year's securities report.」
States that there have been no new business or other risks and no material changes to existing risks. - FY2024-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks, and no material changes to the business or other risks described in the securities report for the previous fiscal year.」
States that there have been no new occurrences or material changes concerning business and other risks. - FY2023RestatedAnnual report
「In Japan, policies to improve the quality of healthcare and contain medical costs are being advanced, and medical fees, drug prices, and official reimbursement prices for specified insured medical materials are revised once every 2 years. Changes in healthcare policy could intensify competition among companies and lead to lower selling prices, potentially affecting the operating results and financial position of the Group.」
Continues to identify revisions to medical fees and other prices, policies to contain medical costs, and the potential for intensified competition and lower selling prices as major risks. - FY2023-Q3RestatedAnnual report
「During the first nine months of the fiscal year, there were no new business risks and no material changes to the business risks described in the previous fiscal year's securities report.」
Reconfirms the view that there have been no new business or other risks or material changes to existing risks. - FY2023-Q1RestatedAnnual report
「During the first quarter of the current consolidated fiscal year, there were no newly arising business or other risks, and no material changes to the business or other risks described in the securities report for the previous fiscal year.」
States that there have been no new business or other risks and no material changes to existing risks. - FY2022RestatedAnnual report
「In Japan, policies to improve the quality of healthcare and contain medical costs are being advanced, and medical fees, drug prices, and official reimbursement prices for specified insured medical materials are revised once every 2 years. Changes in healthcare policy could intensify competition among companies and lead to lower selling prices, potentially affecting the operating results and financial position of the Group.」
Continues to identify revisions to medical fees and other prices, policies to contain medical costs, and the potential for intensified competition and lower selling prices as major risks. - FY2022-Q3RestatedAnnual report
「During the first nine months of the fiscal year, there were no new business risks and no material changes to the business risks described in the previous fiscal year's securities report.」
States that there have been no new business or other risks and no material changes to existing risks. - FY2022-Q2RestatedAnnual report
「During the six-month period ended the second quarter of the current consolidated fiscal year, there were no new business risks or material changes to the business risks described in the previous fiscal year's Annual Securities Report.」
States that there have been no new occurrences or material changes concerning business and other risks in general. - FY2022-Q1RestatedAnnual report
「In the medical equipment industry, medical fees for fiscal 2020 were revised upward overall. However, medical institutions continue to face significant burdens due to the renewed spread of COVID-19.」
Continues to describe the upward revision to medical fees for fiscal 2020 and the burden on medical institutions resulting from the renewed spread of COVID-19. - FY2021RestatedAnnual report
「In Japan, policies to improve the quality of healthcare and contain medical costs are being advanced, and medical fees, drug prices, and official reimbursement prices for specified insured medical materials are revised once every 2 years. Changes in healthcare policy could intensify competition among companies and lead to lower selling prices, potentially affecting the operating results and financial position of the Group.」
Continues to identify revisions to medical fees and other prices, policies to contain medical costs, and the potential for intensified competition and lower selling prices as major risks. - FY2021-Q3RestatedAnnual report
「In the medical equipment industry, medical fees for fiscal 2020 were revised upward overall. However, medical institutions continue to face significant burdens as they respond to COVID-19.」
Reconfirms the upward revision to medical fees for fiscal 2020 and the burden on medical institutions resulting from the response to COVID-19. - FY2021-Q2RestatedAnnual report
「In the medical equipment industry, medical fees for fiscal 2020 were revised upward overall. However, medical institutions continue to face significant burdens as they respond to COVID-19.」
Continues to describe the upward revision to medical fees for fiscal 2020 and the burden on medical institutions resulting from the response to COVID-19. - FY2021-Q1Update to the fiscal 2020 medical fee revisionAnnual report
「In the medical equipment industry, medical fees for fiscal 2020 were revised upward overall. However, medical institutions continue to face significant burdens due to the spread of COVID-19.」
States that medical fees for fiscal 2020 were revised upward overall, while identifying the burden on medical institutions resulting from the spread of COVID-19 as a new development. - FY2020RestatedAnnual report
「In Japan, revisions to medical fees, drug prices, and official reimbursement prices for specified insured medical materials, as well as the expansion of DPC (bundled payment for inpatient medical costs), are being advanced.」
Continues to identify the difficult market environment resulting from revisions to medical fees and reimbursement prices and the expansion of DPC as an issue and risk. - FY2020-Q3Specification of the revision timingAnnual report
「In the medical equipment industry, the April 2018 revision to medical fees was negative overall. Although the revision to medical fees implemented in October 2019 in connection with the increase in the consumption tax rate to 10% was positive overall, medical institutions continue to be required to provide effective, efficient, and high-quality healthcare.」
Replaces the wording used through the previous quarter with specific implementation months and reconfirms the negative revision in April 2018 and the positive revision in October 2019. - FY2020-Q2Update to the content of the medical fee revisionAnnual report
「In the medical equipment industry, medical fees for fiscal 2018 were revised downward overall. Although the fiscal 2019 revision to medical fees, implemented in connection with the increase in the consumption tax rate to 10% in October this year, was positive overall, medical institutions continue to be required to provide effective, efficient, and high-quality healthcare.」
States that medical fees were revised downward overall for fiscal 2018, while the fiscal 2019 revision associated with the increase in the consumption tax rate to 10% was positive overall, updating the situation concerning medical fee revisions. - FY2020-Q1RestatedAnnual report
「In the medical equipment industry, medical fees for fiscal 2018 were revised downward overall, and medical institutions continue to be required to provide effective, efficient, and high-quality healthcare.」
Reiterates the overall downward revision to medical fees for fiscal 2018 and the requirement for medical institutions to provide efficient, high-quality healthcare. - FY2019RestatedAnnual report
「In Japan, revisions to medical fees, drug prices, and official reimbursement prices for specified insured medical materials, as well as the expansion of DPC (bundled payment for inpatient medical costs), are being advanced.」
Continues to identify the difficult market environment resulting from revisions to medical fees and reimbursement prices and the expansion of DPC as an issue and risk. - FY2019-Q3RestatedAnnual report
「In the medical equipment industry, medical fees for fiscal 2018 were revised downward overall, and medical institutions continue to be required to provide effective, efficient, and high-quality healthcare.」
Reiterates the overall downward revision to medical fees for fiscal 2018 and the requirement for medical institutions to provide efficient, high-quality healthcare. - FY2019-Q2MaterialisedAnnual report
「In the medical equipment industry, medical fees for fiscal 2018 were revised downward overall, and medical institutions continue to be required to provide effective, efficient, and high-quality healthcare.」
Reiterates that medical fees for fiscal 2018 were revised downward overall, indicating that the risk related to medical fee revisions also occurred in the quarter. - FY2019-Q1MaterialisedAnnual report
「In the medical equipment industry, medical fees for fiscal 2018 were revised downward overall, and medical institutions continue to be required to provide effective, efficient, and high-quality healthcare.」
Records that medical fees for fiscal 2018 were revised downward overall, indicating that the risk related to medical fee revisions also occurred in the quarter. - FY2018MaterialisedAnnual report
「In the medical equipment industry, medical fees for fiscal 2018 were revised downward overall, and medical institutions continue to be required to provide effective, efficient, and high-quality healthcare.」
Records that the downward revision to medical fees for fiscal 2018 was implemented, indicating that the risk related to medical fee revisions also occurred in the fiscal year. - FY2018-Q3RestatedAnnual report
「In the medical equipment industry, medical fees for fiscal 2016 were revised downward overall, and medical institutions continue to be required to provide effective, efficient, and high-quality healthcare.」
Reiterates the downward revision to medical fees for fiscal 2016 and the requirement for medical institutions to provide efficient, high-quality healthcare. - FY2018-Q2RestatedAnnual report
「In the medical equipment industry, medical fees for fiscal 2016 were revised downward overall, and medical institutions continue to be required to provide effective, efficient, and high-quality healthcare.」
Reiterates the downward revision to medical fees for fiscal 2016 and the requirement for medical institutions to provide efficient, high-quality healthcare. - FY2018-Q1RestatedAnnual report
「In the medical equipment industry, medical fees for fiscal 2016 were revised downward overall, and medical institutions continue to be required to provide effective, efficient, and high-quality healthcare.」
Reiterates the downward revision to medical fees for fiscal 2016 and the requirement for medical institutions to provide efficient, high-quality healthcare. - FY2017RestatedAnnual report
「In Japan, revisions to medical fees, drug prices, and official reimbursement prices for specified insured medical materials, as well as the expansion of DPC (bundled payment for inpatient medical costs), are being advanced. The market environment is expected to remain difficult.」
Reiterates the challenging domestic healthcare policy and market environment, including revisions to medical fees and reimbursement prices and the expansion of DPC. - FY2017-Q3RestatedAnnual report
「In the medical equipment industry, medical fees for fiscal 2016 were revised downward overall, and medical institutions continue to be required to provide effective, efficient, and high-quality healthcare.」
Reiterates the downward revision to medical fees for fiscal 2016 and the requirement for medical institutions to provide efficient, high-quality healthcare. - FY2017-Q2RestatedAnnual report
「In the medical equipment industry, medical fees for fiscal 2016 were revised downward overall, and medical institutions continue to be required to provide effective, efficient, and high-quality healthcare.」
Reiterates the downward revision to medical fees for fiscal 2016 and the requirement for medical institutions to provide efficient, high-quality healthcare. - FY2017-Q1MaterialisedAnnual report
「In the medical equipment industry, medical fees for fiscal 2016 were revised downward overall, and medical institutions continue to be required to provide effective, efficient, and high-quality healthcare.」
Records that the downward revision to medical fees was actually implemented, treating it as the occurrence of an existing risk related to medical fee revisions. - FY2016First statedAnnual report
「In Japan, policies to improve the quality of healthcare and contain medical costs are being advanced, and medical fees, drug prices, and official reimbursement prices for specified insured medical materials are revised once every 2 years. Changes in healthcare policy could intensify competition among companies and lead to lower selling prices.」
States that changes in healthcare policy and the biennial price revisions could intensify competition and lower selling prices.